Mesoblast Reports First Quarter Fiscal 2026 Financial and Operational Results

Mesoblast reported a 44% year-over-year increase in net revenue for the quarter ended September 30, 2026, and an 86% improvement in net operational cash spend. It ended the quarter with US$99 million in cash, while RYONCIL generated US$28 million in net revenue and September saw the quarter’s highest number of new patient starts. The company completed patient treatment in its Phase 3 rexlemestrocel-L trial for chronic inflammatory low back pain and said the FDA had aligned on a BLA filing path for the therapy in LVAD-supported patients with end-stage HFrEF.